A panel of experts discuss myeloproliferative neoplasms, focusing primarily on myelofibrosis, and share their experiences treating these diseases.
EP. 1: An Introduction to Myeloproliferative Neoplasms
Jamile Shammo, MD, FACP, FASCP, provides an overview of the different types of myeloproliferative neoplasms.
EP. 2: Understanding Essential Thrombocythemia And Treatment Options
Stephen Oh, MD, PhD, and Ruben Mesa, MD, explain the fundamentals of essential thrombocythemia (ET) and its treatment options.
EP. 3: What to Know About Polycythemia Vera and Treatment Options
Angela Fleischman, MD, PhD, and Stephen Oh, MD, PhD, discuss polycythemia vera (PV) and the possible therapies that can be used to treat patients.
EP. 4: Monitoring Patients With ET and PV
Jamile Shammo, MD, FACP, FASCP, tells how she would monitor ET and PV based on her personal experience.
EP. 5: MPN Outcomes
The panel describes the possible outcomes for patients with myeloproliferative neoplasms (MPN).
EP. 6: A Myelofibrosis Diagnosis
Dr Fleischman provides details about myelofibrosis (MF) and what factors are considered with a diagnosis.
EP. 7: MF Prognosis and Common Risks
Drs Shammo and Mesa explain the MF prognosis and possible risk factors.
EP. 8: More About MF Prognosis, Biomarkers, and Treatment
The panel continues the MF prognosis discussion while also discussing biomarkers and treatment for the disease.
EP. 9: Determining Treatment for MF And Upfront Therapy Options
A group of experts explain how to determine treatment for each patient with MF, as well as upfront therapy options.
EP. 10: More Upfront Therapy Options for MF
More upfront therapy options for the MF treatment landscape are discussed, including the safety profiles of these drugs.
EP. 11: Selecting a Therapy for Patients With MF
A panel of experts share how they select between treatment options for patients with MF.
EP. 12: Sequencing MF Therapies and Novel Combinations
The panel relays how they would sequence MF therapies, as well as the novel combination therapies that can be used.
EP. 13: Monitoring Patients Being Treated for MF
Dr Oh lists the ways MF can and should be monitored.
EP. 14: The Clinical Course for MF and Changing Therapies
Dr Fleischman explains the clinical course she would take with MF treatment and what it would take to change therapies.
EP. 15: Unmet Needs and Potential Advances in MPN and MF
A group of experts share unmet needs in the treatment of MPN and MF while providing information about potential advances that could impact treatment in the future.
EP. 16: Clinical Pearls for Treating MPN and MF
The panel concludes this discussion with clinical pearls they would like to share with colleagues that treat MPN and MF.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer